The phrase "an ews" is not correct in written English.
It seems to be a typographical error or a misunderstanding, as "ews" does not function as a standalone word that can be preceded by "an."
Example: "I received an ews update about the event." (Note: "ews" should be replaced with a correct term like "news.")
Alternatives: "a news" or "an update."
Jarvis and colleagues developed an EWS based on laboratory blood tests and used it in conjunction with physiological EWS to effectively risk stratify all medical patients [ 2].
They are assessed with the Relative Economic Value REVV), which is a flexible measure to quantify the potential economic benefits of an EWS.
Importantly, the use of an EWS has shown to improve 'observations' records [[27]].
Fiberglass rain gauges were introduced in the communities as an EWS (Wijesinghe 2014).
On the contrary, a track and trigger system based on an EWS may detect early signs of deterioration [[10]].
The authors concluded that an EWS in association with a medical activation algorithm translates into benefits for patients as well as ward staff [[28]].
The Ewing's sarcoma family of tumours (ESFT) is defined by the presence of an EWS-ETS gene rearrangement involving the EWS gene on chromosome 22q12 with one of a number of ETS genes; most frequently with FLI1 on chromosome 11q24 (Turc-Carel et al, 1983; Delattre et al, 1994).
A chimeric transcript of ∼1.8 kb was detected by northern blotting using EWS and Oct-4 probes, and an EWS-Oct-4 fusion transcript, but not the reciprocal Oct-4-EWS fusion transcript, was detected in tumours by RT PCR (Yamaguchi et al, 2005).
The majority of Ewing's sarcoma and primitive neuroectodermal tumours are associated with a t(11 22)(q24;q12) chromosomal translocation, which results in the production of an EWS/FLI-1 fusion protein that comprises the amino terminus of the EWS gene and the carboxyl terminus of the FLI-1 gene.
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in ewing sarcoma.
In Ewing's sarcoma, a poorly differentiated bone/soft tissue cancer that is characterized as sharing a common translocation generating an EWS-ETS fusion, Lyn also appears as a potential therapeutic target [ 104].
